823. New Drugs and Drug Target Development
Session: Symposium: SOS: The Rescue from Antibacterial Resistance?
Saturday, October 22, 2011: 9:15 AM
Room: 104ABC

Michael Dudley, PharmD, FIDSA, Mpex Pharmaceuticals, San Diego, CA

Dr. Michael Dudley currently serves as Senior Vice President, Research and Development and Chief Scientific Officer for Mpex Pharmaceuticals in San Diego. Prior to joining Mpex in 2005, he was Vice President of Preclinical and Clinical Sciences at Diversa Corp. He also previously served as Vice President of Pharmacology and Microbiology at Essential Therapeutics/Microcide Pharmaceuticals from 1997-2003.
Prior to his career in pharmaceutical industry, he held academic appointments as Professor of Pharmacy and Chairman of the Department of Pharmacy Practice at the University of Rhode Island College of Pharmacy (URI), and adjunct Professor of Medicine, Brown University School of Medicine and was based at Roger Williams Medical Center. As an academic researcher, he conducted research in infectious disease, including important clinical studies (Phase I-IV) and pioneering work in describing PK-PD approaches and studies for several classes of antibacterial (e.g., fluoroquinolones, cephalosporins, aminoglycosides), antifungal, and antiviral agents.
Dr. Dudley has published over 100 papers and book chapters describing the evaluation and clinical use of antiinfective agents and treatment of infectious diseases. He has served as an invited speaker at several FDA workshops, ICAAC, and as a consultant on several advisory boards for pharmaceutical industry on antiinfective use and development. He served as an Editor for the journal Antimicrobial Agents and Chemotherapy (1995-2002), and remains on its editorial board. He currently serves as a voting member of the Antimicrobial Susceptibility Testing Subcommittee of the Clinical Laboratory Standards Institute (CLSI; formerly NCCLS), a consensus committee responsible for establishing reference methods for antimicrobial susceptibility testing and its interpretation for clinical laboratories. He was elected to Fellow in Infectious Disease Society of America (FIDSA) and the American College of Clinical Pharmacy (FCCP). He completed undergraduate work at Pepperdine University and his Doctor of Pharmacy (Pharm.D.) from University of California San Francisco (UCSF) in 1980, completed at residency at UCSF, and a fellowship in infectious diseases at Hartford Hospital.

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.